Core Viewpoint - The company is focusing on internationalization as a long-term core development strategy, particularly targeting the EU market for product registration and market expansion [1] Group 1: Business Operations - Currently, the company's exports to the EU market primarily consist of raw materials, which represent a relatively small portion of the overall revenue [1] - Sales in the EU market are mainly conducted through a direct sales model with customers, supplemented by sales through distributors to ensure stable business progress [1] Group 2: Strategic Developments - The company has established a sales subsidiary in the Netherlands and is working on preparations for building a sales and registration system aimed at the EU market, in order to facilitate the future export of formulated products [1] - The company aims to continuously improve its global supply chain and sales layout to enhance its competitiveness in international markets [1]

Investment Rating - The report assigns a rating of "Buy" for the company [5][11]. Core Insights - The company is expected to achieve significant growth in 2025, driven by advancements in AI and automotive software, as well as its internationalization strategy. The projected net profit for the year is expected to increase substantially, with notable contributions from overseas markets [2][11]. - The company is in a new development phase characterized by technological iteration and product innovation, with revenue forecasts of 776 million, 926 million, and 1.103 billion yuan for 2025, 2026, and 2027 respectively, alongside net profits of 79 million, 116 million, and 140 million yuan for the same years [11][20]. Financial Summary - Total revenue is projected to be 639 million yuan in 2023, decreasing to 607 million in 2024, before rebounding to 776 million in 2025, representing a year-on-year growth of 27.8% [4]. - The net profit attributable to the parent company is forecasted to be -15 million yuan in 2023, turning positive with 30 million in 2024 and reaching 79 million in 2025, reflecting a significant increase of 164.2% [4]. - The earnings per share (EPS) is expected to improve from -0.17 yuan in 2023 to 0.85 yuan in 2025 [4]. Revenue and Profitability Forecast - The company’s software technology services are expected to generate revenue of 294.7 million yuan in 2025, with a gross margin of 26% [16]. - Custom software development services are projected to yield 328.6 million yuan in revenue in 2025, maintaining a gross margin of approximately 38% [16]. - Third-party testing services are anticipated to bring in 146.1 million yuan in 2025, with a gross margin of 45.8% [17]. Valuation Analysis - The report suggests a price-to-sales (PS) ratio of 6.3 for 2026, leading to a reasonable valuation of 58.5 billion yuan and a target price of 63.1 yuan per share [11][25].

Investment Rating - The report assigns a rating of "Buy" for the company [5][11]. Core Insights - The company is expected to achieve significant growth in net profit in 2025, driven by advancements in AI and automotive software, as well as its internationalization strategy [2][11]. - The company is in a new development phase characterized by technological iteration and product innovation, with projected revenues of 7.76 billion, 9.26 billion, and 11.03 billion for 2025, 2026, and 2027 respectively [11][25]. - The company emphasizes integrating AI deeply into its automotive software development processes, focusing on core areas of intelligent connected vehicles [11][24]. Financial Summary - Total revenue is projected to be 639 million in 2023, with a forecasted increase to 776 million in 2025, representing a growth rate of 27.8% [4]. - The net profit attributable to the parent company is expected to turn positive, reaching 79 million in 2025, a significant increase from a loss of 15 million in 2023 [4]. - The company’s gross margin is expected to improve, with a projected gross margin of 35.5% in 2025 [18]. Revenue Breakdown - Software technology services are expected to generate revenue of 294.7 million in 2025, with a gross margin of 26.4% [18]. - Customized software development services are projected to bring in 328.6 million in 2025, maintaining a gross margin of approximately 38% [18]. - Third-party testing services are anticipated to generate 146.1 million in revenue in 2025, with a gross margin of 45.8% [17][18]. Valuation Analysis - The report suggests a target price of 63.12, based on a dynamic price-to-sales (PS) ratio of 6.3 for 2026 [5][25]. - The company is considered to have a higher valuation elasticity due to its smaller market capitalization and profit base, indicating potential for significant market growth [25].

格隆汇2月5日丨中电港(001287.SZ)2月5日在接待机构投资者调研时表示，国际化是公司未来发展的重 要方向之一，为推进国际化战略布局，公司目前正在布局设立新加坡子公司作为运营主体，将其作为公 司国际化业务桥头堡，进一步加强与国际国内上下游企业交流与合作，共同构建安全、高效、共赢、可 持续的产业链供应链双循环枢纽。 ...

近日，迪瑞医疗发布2025年度业绩预告。从公告披露内容看，受市场竞争加剧、资产减值等因素影响， 公司2025年经营面临阶段性挑战，国内市场业务发展在短期内出现一定波动。公司正多措并举，积极推 动国内市场业务企稳向好。 值得注意的是，迪瑞医疗预计2025年现金流不仅回正，较去年同期有较大幅度提升。据迪瑞医疗2024年 年度报告及2025年半年度报告显示，公司经营活动产生的现金流量净额分别为-2.95亿元及-8.43万元。 可以看出迪瑞医疗2025年在改善经营现金流方面采取多项举措，应收账款回笼、综合费用控制以及资产 处置方面取得较好进展，不仅有助于公司降低坏账风险，同时补充流动资金，持续优化财务结构。 虽然迪瑞医疗当前业绩面临较大挑战，但出海仍是公司出色的亮点。2025年半年度报告显示，海外营收 达2.24亿元，同比增长24.02%。其中，印度、菲律宾、土耳其等国家同比实现了增长，部分封闭机型正 在进入境外高端医院。 公开资料显示，迪瑞医疗近年来不断加大国际市场投入，国际业务发展稳健并进入收获期，有力推动公 司向外向型体外诊断企业转型。目前，国际业务进入到收获期，在聚焦基础医疗基础上实现了海外高端 用户突破，今 ...

Company Overview - Sichuan Shudao Equipment Technology Co., Ltd. introduced its development history, competitive advantages, and the strategic transformation plan for the "14th Five-Year Plan" [2] - The company is focusing on expanding its industrial fund and exploring business areas in industrial gases and hydrogen energy [4] Overseas Market Expansion - In 2025, the company significantly advanced its overseas business, with new overseas contract amounts increasing substantially compared to the previous year [3] - The company successfully won a contract for a natural gas liquefaction facility in Nigeria worth approximately 4.58 billion RMB, marking its first large-scale LNG project in Africa [3] Hydrogen Energy Investment and Operations - The company plans to develop a comprehensive research and manufacturing capability in the hydrogen energy sector, focusing on deep low-temperature liquid hydrogen technology [4] - It aims to align with national and provincial strategic directives to foster the hydrogen energy industry [4] Industrial Fund Investment Focus - The industrial fund will concentrate on three core areas: industrial gases, LNG, and hydrogen energy, with at least 50% of the fund allocated to industrial gases [5] - The fund will act as a "frontline" for mergers and acquisitions, investing in quality targets before integrating them into the listed company [5] Future Growth Drivers - The core business of deep cold technology equipment serves as a stable revenue source, supporting the company's strategic transition towards gas operations [6] - The company aims to extend its focus to downstream sectors, particularly in industrial gases, LNG, and hydrogen energy, through independent investments and mergers [6] Product and Service Offerings - The company specializes in low-temperature liquefaction and separation technologies, providing equipment for natural gas liquefaction and air separation [7] - It is actively expanding its investment and operational services in industrial gases and hydrogen energy [8] Commercial Aerospace Business - The company is involved in the commercial aerospace sector as a high-end gas equipment supplier, having delivered critical equipment for domestic commercial launch enterprises [8] - It plans to evolve from merely supplying equipment to providing comprehensive services, including fuel supply for commercial aerospace [8]

2026年1月15日，公司甘精胰岛素注射液获得欧盟委员会的上市许可（详情请参考公告：2026-004）。 目前，产品正处于获批后的上市前准备阶段，公司正在全力推进包括市场准入、渠道布局、物流准备等 在内的系列商业化工作，尚未开始商业销售。 公司高度重视全球市场，欧盟是我们重要的战略目标市 场之一。此次获批是公司践行国际化战略的关键一步，未来公司将严格按照上市规则对商业化进展履行 持续信息披露义务。 格隆汇2月5日丨甘李药业(603087.SH)在投资者互动平台表示，在欧美市场，公司和山德士于2018年签 订商业和供货协议。协议约定，在三款生物类似药（甘精、门冬、赖脯）获得批准后，山德士将进行药 品在美国、欧洲及其他特定区域的商业运作，由公司负责药物开发（包括临床研究）及供货等事宜。截 至目前，公司与山德士的合作仍在持续稳步推进。 ...

格隆汇2月5日丨甘李药业(603087.SH)在投资者互动平台表示，在欧美市场，公司和山德士于2018年签 订商业和供货协议。协议约定，在三款生物类似药（甘精、门冬、赖脯）获得批准后，山德士将进行药 品在美国、欧洲及其他特定区域的商业运作，由公司负责药物开发（包括临床研究）及供货等事宜。截 至目前，公司与山德士的合作仍在持续稳步推进。 2026年1月15日，公司甘精胰岛素注射液获得欧盟委员会的上市许可（详情请参考公告：2026-004）。 目前，产品正处于获批后的上市前准备阶段，公司正在全力推进包括市场准入、渠道布局、物流准备等 在内的系列商业化工作，尚未开始商业销售。 公司高度重视全球市场，欧盟是我们重要的战略目标市 场之一。此次获批是公司践行国际化战略的关键一步，未来公司将严格按照上市规则对商业化进展履行 持续信息披露义务。 登录新浪财经APP 搜索【信披】查看更多考评等级 ...

（文章来源：证券日报） 证券日报网2月4日讯 ，箭牌家居在接受调研者提问时表示，在深耕国内市场的同时，公司持续推进国 际化战略，加大海外市场的战略投入。通过与当地经销商合作，加快专卖店及销售网点布局；同时依托 主流海外电商平台拓展线上渠道，并通过品牌合作等多维度推进海外业务发展。得益于上述举措，前三 季度，公司在北美以外市场的收入实现明显增长，但受国际经贸环境变化影响，出口北美市场的业务收 入有所下降，导致总体境外收入同比出现下滑。未来，公司将持续投入资源，稳步推进品牌建设与渠道 拓展，夯实基础，力求实现海外业务的长期可持续发展。 ...

Core Viewpoint - The company is focusing on internationalization strategies to enhance its overseas business scale and brand influence, with ongoing expansion projects in Vietnam and Thailand [1] Group 1: International Expansion - The company is actively expanding its business cooperation in Vietnam and has made smooth progress in constructing a new production base in Thailand [1] Group 2: Product Development and Market Share - The company aims to increase the proportion of high-voltage flat wires for new energy vehicles to 47% by the end of 2025 [1] - In the semiconductor field, the sales volume of copper materials is expected to exceed 40,000 tons, with over 14,000 tons in the computing heat dissipation sector, showing a year-on-year growth rate of nearly 60% [1] - The company is continuously expanding its market share in high-end industries and emerging product applications [1] Group 3: Sustainability and Profitability - The company is seizing opportunities in green and low-carbon development, enhancing its technical reserves and business cooperation in the recycled copper sector [1] - These efforts are aimed at supporting the continuous improvement of the company's overall profitability [1]